MedTrace Logo

Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

NCT03080298 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2017-08-18

No results posted yet for this study

Summary

This is study of the efficacy, safety and pharmacokinetics of BP101 compared to placebo in patients with a decrease or loss of sexual desire.

Conditions

  • Hypoactive Sexual Desire Disorder (HSDD)

Interventions

DRUG

BP101

DRUG

Placebo

Sponsors & Collaborators

  • Ivix LLX

    lead INDUSTRY

Principal Investigators

  • Daniil G Nemenov, MD · IVIX Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-14
Primary Completion
2017-04-04
Completion
2017-07-25

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03080298 on ClinicalTrials.gov